Karyopharm Therapeutics (KPTI) Accounts Payables (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Accounts Payables came in at $4.0 million in Q4 2025, down 21.62% YoY from $5.1 million in Q4 2024, and down 25.76% on a QoQ basis from $5.4 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Accounts Payables (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Accounts Payables data on file, last reported at $4.0 million in Q4 2025.
- Quarterly Accounts Payables fell 21.62% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.0 million (down 21.62% YoY) and the FY2025 annual result came in at $4.0 million, down 21.62% from the prior year.
- Accounts Payables slipped to $4.0 million in Q4 2025, from $5.4 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $9.0 million in Q1 2023 to a low of $813000.0 in Q3 2022.
- A 5-year average of $3.4 million and a median of $2.9 million in 2021 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables plunged 63.98% — and 2024, when it surged 513.26%.
- Tracing KPTI's Accounts Payables over 5 years: stood at $1.6 million in 2021, then soared by 72.99% to $2.8 million in 2022, then grew by 12.62% to $3.1 million in 2023, then soared by 63.53% to $5.1 million in 2024, then retreated by 21.62% to $4.0 million in 2025.
- The last three Accounts Payables figures came in at $4.0 million (Q4 2025), $5.4 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.66 Mn |
| Dec 31, 2025 | 4.00 Mn |
| Sep 30, 2025 | 5.39 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 5.87 Mn |
| Dec 31, 2024 | 5.11 Mn |
| Sep 30, 2024 | 5.78 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Mar 31, 2024 | 5.03 Mn |
| Dec 31, 2023 | 3.12 Mn |
| Sep 30, 2023 | 943,000.00 |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 9.05 Mn |
| Dec 31, 2022 | 2.77 Mn |
| Sep 30, 2022 | 813,000.00 |
| Jun 30, 2022 | 1.69 Mn |
| Mar 31, 2022 | 3.44 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 881,000.00 |
| Jun 30, 2021 | 2.31 Mn |